Epidemic Parotitis Epidemiology Forecast 2026-2035

Epidemic parotitis, commonly referred to as mumps, is a globally endemic viral infection that causes painful swelling of the salivary glands. According to the Centers for Disease Control and Prevention, it occurs worldwide with approximately 500,000 cases reported annually. As per the Epidemic Parotitis Epidemiology Forecast, current global trends and future projections highlight ongoing public health challenges.

Epidemic Parotitis Epidemiology Forecast Report Coverage

The analyst's “Epidemic Parotitis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of epidemic parotitis. It projects the future incidence and prevalence rates of epidemic parotitis cases across various populations. The study covers age, gender, and type as major determinants of the epidemic parotitis population. The report highlights patterns in the prevalence of epidemic parotitis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of epidemic parotitis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Epidemic Parotitis Understanding: Disease Overview

Epidemic parotitis, commonly known as mumps, is an acute viral infection caused by the mumps virus. It primarily affects the parotid salivary glands, leading to painful swelling near the jaw and cheeks. The virus spreads through respiratory droplets, direct contact, or contaminated surfaces. After an incubation period of approximately 16-18 days, symptoms such as fever, headache, muscle aches, and glandular swelling appear. Although often self-limiting, complications may include orchitis, oophoritis, meningitis, and pancreatitis. Mumps can occur in sporadic cases or outbreaks, particularly in unvaccinated populations.

Epidemic Parotitis Epidemiology Perspective

The epidemic parotitis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for epidemic parotitis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for epidemic parotitis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Jamie Tappe et al., 2024, approximately 20% of mumps infections among unvaccinated individuals are asymptomatic, while the prevalence among vaccinated persons remains unknown. Mumps cases declined substantially after the onset of the COVID-19 pandemic, although sporadic cases continue, predominantly among children younger than 10 years.
• As per Mioljub Ristić et al., 2025, mumps is an acute viral illness caused by the mumps virus of the Paramyxoviridae family, with 20 to 40% of infections in unvaccinated children remaining asymptomatic. This high proportion of subclinical cases contributes to underestimation of true prevalence and ongoing community transmission.
• According to Narmatha K et al., 2024, the incubation period typically ranges from 16 to 18 days and may extend up to 25 days. Parotitis usually lasts about 5 days and may be unilateral or bilateral, with prodromal symptoms increasing the period of infectivity and influencing incidence patterns.
• As per Tulika Goswami Mahanta et al., 2025, the highest prevalence was reported in the 1 to 15 years age group, accounting for 41% of cases, while only 3% occurred in individuals aged 61 to 75 years. Gender distribution showed 54% males and 46% females, indicating slight male predominance and low mortality with notable morbidity.

Country-wise Epidemic Parotitis Epidemiology

The epidemic parotitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered regions, the epidemiology of Epidemic Parotitis reflects both sustained control and periodic resurgence. According to Ritik Agrawal et al., 2025, the World Health Organization estimated approximately 500,000 mumps cases annually worldwide, with 384,785 cases reported in 2023, representing a 1% increase from the previous year. Europe, including the United Kingdom, Germany, France, Spain, and Italy, experienced resurgence during 2021-2022, particularly among individuals aged 10 years and older. In the United States, outbreak-related economic burden was estimated at USD 9,459 per case. As per the Institute for Quality and Efficiency in Health Care, 2023, incidence in Germany declined from approximately 200 per 100,000 annually before vaccination to around 1 per 100,000 currently, mainly affecting adolescents and young adults, while Japan continues to report periodic outbreaks linked to vaccination coverage variations.

Epidemic Parotitis: Treatment Overview

There is no specific antiviral therapy for epidemic parotitis; management is primarily supportive. Treatment focuses on relieving symptoms and preventing complications. Adequate rest, hydration, and the use of analgesics and antipyretics such as paracetamol or ibuprofen are recommended to control pain and fever. Warm or cold compresses may reduce glandular discomfort. Patients are advised to maintain isolation for at least five days after the onset of parotid swelling to prevent transmission. Vaccination with the MMR vaccine is the most effective preventive strategy, significantly reducing disease incidence and outbreak severity.

Key Questions Answered

• What are the key findings of epidemic parotitis epidemiology in the 8 major markets?
• What will be the total number of patients with epidemic parotitis across the 8 major markets during the forecast period?
• What was the country-wise epidemic parotitis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of epidemic parotitis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of epidemic parotitis during the forecast period of 2026-2035?
• What are the currently available treatments for epidemic parotitis?
• What are the risks, signs, symptoms, and unmet needs of epidemic parotitis?

Scope of the Epidemic Parotitis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of epidemic parotitis based on several factors.
• Epidemic Parotitis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The epidemic parotitis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.